Armodafinil
From Wikipedia, the free encyclopedia
|
Armodafinil
|
|
| Systematic (IUPAC) name | |
| (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C15H15NO2S |
| Mol. mass | 273.351 |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic, including CYP3A4 and other pathways |
| Half life | 12-15 hrs |
| Excretion | Urine (as metabolites) |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status |
Schedule IV (USA) |
| Routes | Oral |
Armodafinil (Nuvigil) is a stimulant drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007.[1]
Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition associated with schizophrenia, and excessive sleepiness and fatigue in conditions such as Parkinson's disease and cancer.[2]
Nuvigil is protected by a U.S. patent expiring in 2023 that claims the Form 1 polymorph of armodafinil.
[edit] See also
[edit] References
- ^ CDER Drug and Biologic Approvals for Calendar Year 2007. Retrieved on 2008-01-21.
- ^ Cephalon - Pipeline,. Retrieved on 2008-01-21.
|
|||||||||||||||||||||||

